Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096385 | 0.87 | TDP1 (0.47) | TDP1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13118736 | 0.80 | TDP1 (0.57) | TDP1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10330877 | 0.77 | TDP1 (0.53) | TDP1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10153183 | 0.77 | GAA (0.56) | TDP1GAAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL14248201 | 0.76 | GAA (0.55) | TDP1GAAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL20096366 | 0.76 | CUL4A (0.36) | TDP1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10129233 | 0.74 | GAA (0.59) | TDP1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL28052753 | 0.74 | ALDH1A1 (0.34) | TDP1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2267031 | 0.71 | GAA (0.50) | TDP1GAAMAPTMEN1KMT2A | |
| SCHEMBL10113793 | 0.71 | MAPT (0.65) | GAAMAPTALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063392-A | Improved process for preparing statin precursors | 灿盛制药有限公司荷兰公司 | 2024-05-24 | — | — | CN | disclosed |
| US-10246423-B2 | Process for preparing statin precursor | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2019-04-02 | — | — | US | disclosed |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-04-26 | — | — | US | disclosed |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-04-26 | — | — | US | disclosed |
| US-20180016241-A1 | IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2018-01-18 | — | — | US | disclosed |
| US-20180016241-A1 | IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2018-01-18 | — | — | US | disclosed |
| CN-107428702-A | Improved process for preparing statin precursors | 中化帝斯曼制药有限公司荷兰公司 | 2017-12-01 | — | — | CN | disclosed |
| WO-2016151104-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016151104-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016116589-A1 | IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2016-07-28 | — | — | WO | disclosed |
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| WO-2012172564-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | DR. REDDY'S LABORATORIES LIMITED (IN) | 2012-12-20 | — | — | WO | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | TDP1 1584/4885GAA 347/4885MAPT 1208/4885 |
| US-20180016241-A1 | IMPROVED PROCESS FOR PREPARING STATIN PRECURSOR | HMGCR, STS, DHPS | TDP1 1848/4885GAA 2113/4885MAPT 3341/4885 |
| US-20180111906-A1 | IMPROVED PROCESS FOR PREPARING A STATIN PRECURSOR | HMGCR, CYP11B1, OSBP | TDP1 1289/4885GAA 2141/4885MAPT 1599/4885 |
| US-10246423-B2 | Process for preparing statin precursor | HMGCR, STS, DHPS | TDP1 1969/4885GAA 2629/4885MAPT 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.